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Abstract: Both autosomal dominant and recessive polycystic kidney disease are conditions with 
severe associated morbidity and mortality. Recent advances in the understanding of the genetic 
and molecular pathogenesis of both ADPKD and ARPKD have resulted in new, targeted thera-
pies designed to disrupt cell signaling pathways responsible for the abnormal cell proliferation, 
dedifferentiation, apoptosis, and fluid secretion characteristic of the disease. Herein we review 
the current understanding of the pathophysiology of these conditions, as well as the current 
treatments derived from our understanding of the mechanisms of these diseases.
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Introduction
Polycystic kidney disease (PKD) is an inherited disorder characterized by cystic 
expansion of the kidneys producing progressive kidney enlargement and renal 
insufficiency, in addition to various extrarenal manifestations. The disease can be 
inherited in autosomal dominant and recessive forms. Autosomal dominant polycys-
tic kidney disease (ADPKD) is characterized by slow but progressive enlargement 
of the kidneys with renal failure occurring by the fifth to sixth decade of life.1 The 
disease occurs in approximately 1:800 to 1:1,000 people and accounts for 2.5% of 
all cases of end-stage renal disease.1,2 Clinically, ADPKD presents over the course 
of decades with hypertension, flank pain, hematuria, and renal cyst infections in 
adults. Cyst development and growth is gradual, yet despite the massive growth 
of the kidneys (Figure 1), the glomerular filtration rate (GFR) in these patients is 
typically conserved until ages 30–40, followed by a rapid, linear decline after this 
time.2,3 By the age of 70, 50% of patients with ADPKD will require dialysis or 
kidney transplantation.4
Autosomal recessive polycystic kidney disease (ARPKD), by contrast, typically 
presents in a younger patient population.5 The disease is characterized by cystic dilation 
of the collecting ducts of the kidneys, along with dysgenesis of the biliary ductal plate, 
resulting in congenital hepatic fibrosis and often death in the perinatal period due to 
respiratory failure.6,7 The disease has an estimated incidence of 1 out of 20,000 live 
births and presents with four distinct phenotypes as proposed by Blyth and Ockenden, 
differentiation based on the age of presentation, the amount of biliary fibrosis, and the 
proportion of dilated renal collecting ducts.7–9 Despite varying clinical presentations, 
all phenotypes have been linked to a single gene, PKHD1.10International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Figure 1 Explanted polycystic kidneys reveal the massive expansion resulting from progressive cystic growth.
Clinical presentation
ADPKD
The majority of patients with ADPKD have few or no symp-
toms at the time of diagnosis. When symptoms do occur, they 
typically begin between 30 to 50 years of age, and most com-
monly include acute abdominal or flank pain.11,12 The most 
common clinical manifestation of ADPKD is hypertension, 
which has been found to be present in as many as 60% of 
patients before the impairment of renal function, and nearly 
all patients by the time they progress to ESRD.13–15 Other 
presenting signs and symptoms include palpable kidneys, 
microscopic or gross hematuria, recurrent urinary tract 
infections, lower back discomfort, shortness of breath, and 
early satiety.16
The most common extrarenal manifestation of ADPKD is 
the development of hepatic cysts, which usually occur after 
the development of renal cysts, and are incidental findings in 
most patients.17 Other findings in ADPKD include pancreatic, 
thyroid, subarachnoid, and seminal vesicle cysts.1 The most 
lethal extrarenal manifestations of ADPKD are intracranial 
aneurysms, which has been found to be present in up to 
40% of ADPKD patients.18 These aneurysms can rupture, 
causing intracranial hemorrhage and death in 8% to 11% of 
patients. Additional vascular findings in ADPKD include 
cardiac valvular disease, and less commonly, thoracic, iliac, 
and abdominal aortic aneurysms, coronary artery aneurysms, 
intracranial arterial dissection, intracranial arterial dolichoe-
ctasia, and megadolichobasilar artery.19–23
Nephrolithiasis is another common complication of 
ADPKD, occurring in 20%–30% of patients.24 Stone for-
mation should be suspected in any ADPKD patient with 
an acute onset of pain, hematuria, or deteriorating kidney 
function. Stone composition is typically uric acid or calcium 
oxalate, with decreased ammonia excretion, low urinary 
pH, low citrate concentration, and urinary stasis thought to 
contribute to stone formation.12 The presence of stones can International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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be confirmed with either renal ultrasonography (US) or CT 
scanning, with the   latter being better at detecting stones given 
the limitations of US in the presence of parenchymal or cyst 
wall calcifications.25
ARPKD
ARPKD has a variable clinical presentation and age of onset, 
with most cases being diagnosed in utero or shortly after birth. 
In the most severe cases, ARPKD can be detected in utero 
by the presence of very large echogenic kidneys that occupy 
much of the abdominal cavity, along with oligohydramnios, 
due to inadequate renal development.5,26 These patients 
typically display the characteristic ‘Potter’ phenotype, 
with findings that include pulmonary hypoplasia, extremity 
abnormalities, unusual facial appearances, and deformities of 
the spine, all of which can be attributed to lack of amniotic 
fluid.5 These patients often die in the neonatal period due to 
respiratory complications rather than renal failure, with their 
renal insufficiency rarely severe enough to be fatal.5 Liver 
disease in this age group is typically insignificant, although 
microscopic disease can be seen.27,28 Delayed presentations 
are also possible with ARPKD, with some patients having no 
clinical or laboratory abnormalities until later in childhood.27 
Presenting signs and symptoms in these patients are often 
due to complications of congenital hepatic fibrosis, which 
include portal hypertension, cholangitis, and hepatomegaly. 
Abnormal laboratory findings can also lead to the diagnosis 
in these patients, and may include asymptomatic elevated 
creatinine, hematuria, proteinuria, and hypertension.
Other manifestations of ARPKD include electrolyte 
abnormalities, most commonly hyponatremia, and urinary 
tract infections from enteric organisms, including Escheri-
chia coli, Enterobacter, and Klebsiella.7 Extrarenal cysts 
are less commonly seen in ARPKD compared to autosomal 
dominant disease, but have been reported in the liver and 
pancreas.29 Intracranial aneurysms have also been described, 
although this finding is extremely rare, possibly due to the 
low average life-expectancy in this group of patients.30,31
Evaluation and diagnosis
ADPKD
When ADPKD is suspected, patients should be evaluated for 
a family history of disease, with specific questioning span-
ning three generations. Although no consensus criteria have 
been established, with a negative family history of disease, a 
presumptive diagnosis can be made when there are bilateral 
renal cysts, and when two of the following criteria are met: 
bilateral renal enlargement, more than two hepatic cysts, 
presence of a cerebral aneurysm, or if there is a solitary cyst 
in the arachnoid, pineal gland, pancreas, or spleen.32 Given 
that the number of renal cysts increases with age, it has 
been proposed that three or more cysts, either unilaterally 
or bilaterally, is sufficient to make the diagnosis in patients 
between 15 to 39 years of age.33 Likewise, patients between 
the ages of 40 and 59 require at least two cysts in each kidney, 
with at least four cysts required in each kidney to make the 
diagnosis in patients aged 60 and above. Although magnetic 
resonance imaging and computed tomography are likely more 
sensitive for cyst detection, ultrasound (US) is currently the 
imaging modality of choice in these patients.11,33 A gene-
based diagnosis of ADPKD is also possible, allowing for the 
detection of specific PKD1 or PKD2 mutations. This testing 
is not commonly performed, however, given the expense of 
the test and its ability to detect definitive mutations in only 
41%–63% of cases.34,35
ARPKD
Autosomal recessive PKD can typically be diagnosed based 
on clinical findings alone, with liver and kidney biopsies 
needed only in rare instances (Table 1).36–38 In utero, the 
diagnosis is suggested by the presence of oligohydramnios, 
kidney enlargement, and the absence of urine in the fetal 
bladder, findings typically detectable by US at 18–20 weeks 
gestation. DNA analysis by amniocentesis or chorionic villus 
sampling is currently not part of the routine evaluation of 
ARPKD patients, with its use typically limited to uncertain 
cases or for prenatal confirmation.39
Inheritance
ADPKD
ADPKD results from mutations in the genes PKD1 or PKD2, 
which encode the proteins polycystin-1 and polycystin-2, 
respectively, with PKD1 being located on the short arm of 
chromosome 16 (16p13.3 region) and PKD2 on the long 
arm of chromosome 4 (4q21.2 region).1,40 Approximately 
eighty-five percent of cases of ADPKD have been found to 
Table 1 Diagnostic criteria for ARPKD. Modified from Zerres et al37
Imaging criteria
 •  Characteristic findings on US, as defined by Garel et al38
Clinical criteria
 •  Absence of renal cysts in both parents by US
 •  Signs of hepatic fibrosis
 •  Pathoanatomical proof of ARPKD in an affected sibling
 •  Parenteral consanguinity
Notes: *To meet diagnostic criteria, patients must meet imaging criteria and at least 
one of the clinical criteriaInternational Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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be associated with mutations in PKD1, with the other 15% 
due to PKD2 mutations.1,4 Mutations in PKD1 and PKD2 
produce phenotypically similar presentations, however, as 
a group, patients with PKD1 mutations generally have a 
larger number of renal cysts and progress more rapidly to 
end-stage renal disease.11,41,42 As the name suggests, ADPKD 
is inherited in an autosomal dominant fashion and has nearly 
complete penetrance. The disease is characterized by a ‘sec-
ond hit’ phenomenon, in which a mutated dominant allele is 
inherited from a parent, with cyst formation occurring only 
after the normal, wild-type gene sustains a second genetic 
‘hit’, resulting in renal tubular cyst formation and disease 
progression.11 Some data suggests that those individuals 
with milder disease courses may have incompletely pen-
etrant PKD1 alleles, indicating that the level of functional 
PKD1 protein may be important for cyst initiation.43 There 
is also some suggestion that patients that inherit ADPKD 
from their father experience less severe disease, compared 
to maternally-inherited disease.44 Patients with heterozy-
gous mutations of both PKD1 and PKD2 experience worse 
outcomes and more severe disease than those with either 
mutation alone, and homozygosity of PKD1 mutations is 
thought to be lethal in utero.45,46 Notably, there is a large 
amount of intrafamilial variability in ADPKD, with the dif-
ference in the age of ESRD found to be significantly higher 
in siblings (6.9 ± 6.0 years) compared to monozygotic (MZ) 
twins (2.1 ± 1.9 years), suggesting a role for modifier genes 
that might contribute to this variability.47
Some families with ADPKD display neither PKD1 nor 
PKD2 mutations, suggesting that other genetic loci may 
also be associated with the disease.48–52 In general, these 
patients have milder disease, although a number of families 
with more severe clinical courses have been described.52,53 
Reasons for this phenotype heterogenicity are unclear, and 
it is possible that more than one unknown gene is causative 
in these unlinked families.53
ARPKD
ARPKD is a disease primarily of infants and children and 
is caused by mutations at a single locus, the Polycystic 
Kidney and Hepatic Disease 1 gene (PKHD1), located on 
chromosome 6p12.10 PKHD1 encodes the protein fibrocystin 
which, similar to polycystin-1 and polycystin-2, has been 
found to localize in the primary cilium and basal body of 
the renal and bile duct epithelium.54 There are currently over 
300 recognized mutations in PKHD1, with the most severe 
cases often the result of truncating mutations, often resulting 
in perinatal or neonatal death.55–60 Only about 10%–20% of 
cases of ARPKD are associated with commonly occurring 
PKHD1 mutations, with the majority of mutations being 
rare variants and as many as one third of all mutations 
seen exclusive in single families.61,62 Correlations between 
ARPKD genotypes and phenotypes are limited, but studies 
have found genotypes consisting of two truncating mutations 
to be lethal, and those with at least one missense mutation 
to be compatible with life, likely through production of a 
partially-functional protein product.63
Pathophysiology
Recent evidence suggests that the primary abnormality lead-
ing to cyst formation in both the autosomal dominant and 
recessive forms of PKD is related to defects in cilia-mediated 
signaling activity.40 Specifically, PKD is thought to result 
from defects in the primary cilium, an immotile, hair-like 
cellular organelle present on the surface of most cells in 
the body, anchored in the cell body by the basal body.40,64 
In the kidney, primary cilia have been found to be present on 
most cells of the nephron, projecting from the apical surface 
of the renal epithelium into the tubule lumen.64 In response 
to fluid flow over the renal epithelium, the primary cilium 
is bent, resulting in a flow-induced increase in intracellular 
calcium.65
In a 2009 review of the pathogenesis of PKD, Patel et al 
discuss the accumulating evidence supporting the role of 
the primary cilium in PKD.40 They note the identification 
of polycystin-1, polycystin-2, and fibrocystin, the proteins 
associated with ADPKD and ARPKD, within the primary 
cilia and basal body of renal tubular epithelia, suggesting that 
defects in these proteins and subsequent cilia formation may 
lead to PKD.66 The same has been found to be true for other 
cyst-producing conditions, including nephronophthisis and 
Bardet–Biedl syndrome, where causative proteins have also 
been localized to the primary cilia and basal body. Additional 
evidence for the role of the primary cilium in PKD comes 
from the finding that transgenic mice with kidney-specific 
knockouts of Kif3a, a motor protein subunit required for 
cilia formation, produce renal cysts in mice similar to those 
seen in human PKD.67 While it is not known how defects in 
the primary cilium lead to cyst development, it is thought to 
possibly be related to disruption of one of the many signal-
ing pathways regulated by the primary cilium, including 
intracellular calcium, Hedgehog, Wnt/β-catenin, cyclic 
adenosine monophosphate (cAMP), or planar cell polarity 
(PCP).40,68,69
PCP refers to the coordinated orientation of cells making 
up most of the organs of the body in a plane vertical to the International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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apical/basal axis of the cell sheet.70 PCP is thought to play 
an essential role in the organogenesis of numerous organ 
systems through direction of cell migration, polarized cell 
division, and cellular differentiation, with disruption of this 
organization thought to play an important role in the etiol-
ogy of PKD.40 The role of PCP in the etiology of PKD was 
originally demonstrated by Fischer et al who found that 
PCK rats (carrying mutations in PKHD1), had randomized 
patterns of cell division, contributing to tubular dilation 
and cyst formation.69 This was in comparison to wild-type 
renal tubules, which were found to divide along an axis 
roughly parallel to the longitudinal axis of the tubule. This 
polarity is thought to be regulated by the primary cilium, as 
mice with the inactivated Kif3a gene have also been found 
to display disorganized cell division, suggesting disrupted 
PCP.71 Similar findings have been found with inactivation 
of other genes required for ciliogenesis, strengthening the 
role of the primary cilium in the regulation of PCP.72 Recent 
evidence suggests that disrupted PCP may play a role solely 
in the pathogenesis of ARPKD, as mouse models of PKD1 
and PKD2 mutations have been found to lose cell-oriented 
division only after cyst formation has begun, unlike models 
of PKHD1.73
Accordingly, with mutations in PKD1, PKD2, or PKHD1, 
function of the primary cilium is impaired, resulting in dis-
ruption of a number of intracellular signaling cascades that 
produce dedifferentiation of cystic epithelium, increased 
cell division, increased apoptosis, and loss of resorptive 
capacity.74,75 These signaling pathways have been found to 
include cAMP-activated, Wnt signaling, and mammalian tar-
get of rapamycin (mTOR) pathways, the discoveries of which 
have greatly expanded the number of potential therapeutic 
targets for the disease.76 Ultimately, cyst growth and expan-
sion compresses renal vessels and leads to intrarenal ischemia 
and activation of the renin-angiotensin-aldosterone system 
(RAAS), in turn producing progressive cyst   expansion, 
increased systemic vascular resistance, sodium retention, 
and renal fibrosis.77
Vascular manifestations of ADPKD are thought to also 
be related to abnormal functioning of polycystin-1 and 
polycystin-2, which additionally have been found to be 
expressed in vascular smooth muscle and endothelium.78,79 
Polycystin-1 and polycystin-2 associate with one another and 
form a ‘receptor-ion channel complex’ on the membrane of 
primary cilia of renal epithelial cells as well as endothelial 
cells. Here, luminal sheer stress is thought to be sensed 
by polycystin-1, opening the calcium-permeable channel 
polycystin-2 which leads to a series of calcium-dependent 
signaling cascades.80–82 When this mechanosensory function 
is lost in ADPKD, calcium signaling is disrupted, contribut-
ing to cyst formation and numerous vascular alterations.83 
More recently, studies have suggested a role for polycystins 
in pressure-sensing within arterial myocytes, showing that 
the ratio of polycystin-1 to polycystin-2 regulates the opening 
of stretch-activated cation channels, modulating the arterial 
response to changes in intraluminal pressure.84 Additional 
work has revealed that a reduced dose of PKD1 in mouse 
models is associated with vascular dysfunction, resulting 
in age-dependent increases in vascular reactivity.85 This 
reactivity is thought to be the result of altered intracellular 
calcium homeostasis and compensatory changes in transport 
proteins involved in calcium signaling, producing alteration 
of endothelium-dependent relaxation and increased systolic 
blood pressures. Accordingly, PKD1 haploinsufficiency, 
and dosages of polycystin-1 and -2, are thought to play an 
important role in vascular smooth muscle intracellular cal-
cium homeostasis, and thus in the pathogenesis of vascular 
changes seen in ADPKD.
Prognosis
ADPKD
Children with ADPKD are usually asymptomatic. None-
theless, it is estimated that as many as 1%–2% of patients 
may present with early-onset disease, defined as symptoms 
occurring prior to age 15.86 In fact, in the most severe cases, 
ADPKD may present with significant neonatal and perinatal 
morbidity and mortality, a clinical course more characteristic 
of ARPKD.87 More commonly, symptoms of disease begin 
between the ages of 30 to 50, and include acute abdominal 
or flank pain and gross or microscopic hematuria.11
Despite the slow and steady cystic growth in ADPKD 
patients, renal function is maintained for years and even 
decades, typically remaining stable until a critical kidney 
size is reached, after which the decline in GFR is rapid.3 
Support for this theory comes from a study of 284 patients 
with ADPKD which found the onset of ESRD to occur in 
all patients within 5 years of the kidneys being palpated on 
physical examination.88
Much of our data on the natural history of ADPKD 
comes from a cohort of patients representing the Consor-
tium for Radiologic Imaging Studies in Polycystic Kidney 
Disease (CRISP), a group of 241 ADPKD patients between 
the ages of 15 to 45, all of whom had creatinine clearances 
greater than 70 mL/min (Table 2).89 Using standardized MRI 
renal imaging, these patients were evaluated annually for 
3 years in order to determine reliable measures of   disease International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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  progression early in ADPKD.1 As a result, in a series of 
separate   investigations, the CRISP cohort confirmed the 
notion that cystic growth and renal enlargement is significant 
prior to impairment of renal function.89,90 The cohort also 
revealed that normotensive patients have smaller cyst and 
renal volumes compared to hypertensive counterparts. Cys-
tic liver disease was found to be prevalent in ADPKD, with 
83% of the CRISP cohort having liver cysts, women being 
more affected than men and with a great total cyst volume. 
In patients over the age of 35 years, 94% displayed liver 
cysts, while only 55% of patients younger than 25 years of 
age had them.91 Polycystic liver disease can also occur as a 
genetically-independent entity, characterized by numerous 
liver cysts, but without renal involvement. Like ADPKD, 
the disease is inherited in an autosomal dominant fashion, 
with the majority of cases linked to mutations in two sepa-
rate genes, PRKCSH and SEC63.12 These genes encode the 
glucosidase II β subunit and the protein SEC63 and are 
involved in glycoprotein processing within the endoplasmic 
reticulum, with the molecular mechanism of cyst formation 
remaining unclear.12,92
CRISP participants were found to have a mean renal 
growth rate of 5.3% ± 3.9% per year, or about 63.4 mL/year, 
with cyst growth and renal enlargement found to be a continu-
ous and steady process in most patients.90 This was shown by 
Grantham et al who studied the ADPKD cohort with serial 
measurements of total kidney and cyst volumes over the 
3-year study. The investigators found that, in addition to their 
continuous and static growth rates, the increase in cyst volume 
appeared to be largely individualized, varying from patient to 
patient. Moreover, in most patients the kidneys grew at a simi-
lar rate bilaterally, leading the authors to conclude that cysts 
within ADPKD patients were likely programmed to grow 
at uniform rates that can vary from patient to patient. This 
finding has practical prognostic implications,   specifically, that 
ADPKD patients with larger kidneys at any given age will 
likely experience more complicated and rapid clinical courses 
compared to similarly-aged patients with smaller kidneys. 
Evidence for this assumption comes from the study, which 
found that patients younger than 30 with large kidneys, greater 
than 1500 mL, demonstrated the greatest kidney growth rate 
of all ADPKD patients (12.7% per year).90
An important prognostic factor in ADPKD is the geno-
type of the patient, with PKD1 mutations having being found 
to result in earlier onset hypertension and younger end-stage 
renal disease compared to patients with PKD2 mutations.93–96 
This again was shown in the CRISP cohort, where patients 
with PKD2 mutations were found to have significantly 
smaller renal volumes and fewer cysts.41,89 Notably, the rate 
of cyst growth was not found to be significantly different 
between PKD1 and PKD2 patients. Additional studies have 
found the mean age to ESRD to be 53 in patients with PKD1 
mutations, compared to 69 in patients with PKD2.94 Addi-
tional factors found to have negative prognostic implications 
in ADPKD include a younger age at diagnosis, male gender, 
hypertension, increased left ventricular mass, hepatic cysts in 
women, three or more pregnancies, gross hematuria, urinary 
tract infections in men, and increased renal volume.96
Given the success of renal replacement therapy in 
ADPKD, cardiovascular complications have emerged as 
a major cause of morbidity and mortality in this group.97,98 
Hypertension has been found to be nearly universally pres-
ent in ADPKD patients with ESRD, with left ventricular 
hypertrophy seen in over 70% of these patients when begin-
ning dialysis.15,99 This finding is a risk factor for premature 
cardiovascular death, and is an important cause of morbidity 
and mortality in ADPKD patients.100 Moreover, given the 
association between ADPKD and intracranial aneurysms, 
patients with family members with ruptured intracranial 
aneurysms should be screened for evidence of disease, as 
familial clustering of cases has been noted.101
ARPKD
The natural history of autosomal recessive polycystic kidney 
disease is variable, but has been well described in a number 
of retrospective studies following these patients over time. 
These reports have found the 1-year death rate for ARPKD 
varying widely from 9%–81%, with the majority of stud-
ies falling between 9%–13%.7,28,37,102–104 The most common 
causes of death include respiratory failure or sepsis. In a 
recently described cohort of 31 patients with ARPKD fol-
lowed between 1990 and 2000, 55% of patients were found 
to present in the neonatal period, with the most common 
Table 2 Select findings from the CRISP cohort
•   The rate of cyst growth is continuous but heterogeneous, varying from 
individual to individual
•     The mean renal growth rate was found to be 5.3% per year, or about 
63.4 mL per year
•   Larger kidneys have a faster rate of growth and are associated with a 
more rapid disease course
•   PKD1 genotypes are associated with larger kidneys compared to 
PKD2 patients, with no significant difference in cyst growth rate
•   Normotensive patients have smaller cyst and renal volumes compared 
to hypertensive counterparts
•   Cystic liver disease was present in 83% of participants, increasing in 
incidence with patient ageInternational Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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clinical signs being respiratory distress or palpable kidneys 
on   physical examination.7 Pulmonary complications are 
extremely common in the newborn period, and have been 
found to occur in anywhere from 13%–75% of ARPKD 
patients, with ventilatory support being temporarily required 
in 40% of cases.7,86,102,105 The requirement of neonatal ventila-
tory support has been thought to be a negative prognostic fac-
tor, as it often implies more severe pulmonary hypoplasia and 
is associated with greater renal complications.7,106 Patients 
diagnosed as neonates who do not experience significant 
respiratory complications may have a better prognosis, with 
studies finding that renal clearances often improve in the first 
two years of life in these patients, later stabilizing before 
  declining in adolescence.7,102 Some suggest that another 
important prognostic factor in ARPKD is the age of disease 
onset, with a number of studies having shown that the later the 
age of diagnosis, the better the long term survival.102,103,107,108 
The data for this is conflicting, however.7,103,105 Overall, sur-
vival of ARPKD patients at 9 years of age has been found 
to be as high as 80%.7
Patients with ARPKD frequently experience congeni-
tal hepatic fibrosis, which has been found to be present in 
11%–47% of patients, with patients that have delayed presen-
tations often having more significant liver disease.7,27,28,37,102–104 
The most common complication of hepatic fibrosis is portal 
hypertension, seen in 20% to 60% of patients, resulting in 
esophageal varices and bleeding in as many as 20%–36% of 
cases.37,102,107 Nonetheless, portal hypertension rarely affects 
hepatic function, and its complications are uncommonly fatal 
in ARPKD.107 Systemic hypertension is also seen in these 
patients, frequently most severe in infancy. As these patients 
age, hypertension has been shown to gradually decrease in 
severity, with some individuals even returning to normoten-
sive states.7,37,103,107,109
Treatment
Prevention of progression
ADPKD
Hypertension is a common and early manifestation of disease 
in ADPKD and, when uncontrolled, is associated with an 
earlier progression to end-stage renal disease and cardio-
vascular complications, compared to normotensive ADPKD 
patients.14,89,96,97 While it is recognized that hypertension 
affects renal and patient outcomes in ADPKD, the most ben-
eficial antihypertensive medication in this patient population 
remains unclear, with agents that block the renin–angiotensin–
aldosterone system (RAAS) historically thought to be the most 
effective at treating ADPKD-associated hypertension.
Previous studies analyzing the benefit of RAAS blockade 
utilizing angiotensin-converting enzyme (ACE) inhibitors 
have revealed that hypertensive patients with ADPKD treated 
with diuretics have a faster rate of decline in GFR compared 
to patients treated with ACE inhibitors, despite similar blood 
pressure control.110 However, in a head-to-head comparison, 
enalapril has been shown to have no advantage over the cal-
cium-channel blocker amlodipine in slowing GFR decline.111 
Similarly, enalapril has been found to be no more effective 
than atenolol in slowing the decline in renal function, also 
showing no renoprotective effect when used preemptively in 
normotensive ADPKD patients.112
However, weaknesses of the aforementioned studies 
include that older patients were primarily studied, that there 
was limited follow-up, and that non-standardized medication 
dosing was used. Moreover, various different end-points were 
used in each study, and they primarily relied on outcomes 
measures, including GFR, which are ineffective measures 
of treatment efficacy early in the disease course due to the 
long presymptomatic phase of disease and delayed onset of 
renal insufficiency.1,2
While the data surrounding RAAS inhibition in ADPKD 
is still controversial, there remains evidence of increased 
circulating levels of plasma renin and aldosterone in ADPKD 
individuals, suggesting a continued role for RAAS inhibit-
ing medications.113 Likewise, short-term therapy with ACE 
inhibitors has been shown to improve renal blood flow 
and proteinuria in ADPKD patients, with additional stud-
ies showing significant improvements in proteinuria and 
creatinine doubling with use of combination ACEI/ARB 
therapy in other proteinuric renal diseases.1,111,114,115 Accord-
ingly, using novel MRI techniques developed in CRISP to 
evaluate changes in renal volume over short periods of time, 
the Halt Progression of Polycystic Kidney Disease (HALT 
PKD) network was developed to assess whether tight blood 
pressure control and rigorous blockade of RAAS could 
slow the progression of renal disease, as well as prevent 
cardiovascular complications of ADPKD.1 In particular, 
this study tests the efficacy of ACE inhibitors in combina-
tion with angiotensin receptor blockers. The logic for this 
approach comes from the incomplete blockade of RAAS seen 
with ACE inhibitor use alone, given the possibility of ACE-
independent routes of angiotensin II generation, including 
the chymase pathway.116
Accordingly, the study recruited 1020 patients with 
the effects of combination therapy of ACE inhibitors and 
ARBs being tested in early disease (study A) and in cases 
of more advanced renal disease (study B). Study A   consists International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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of 548 patients, all of which have a GFR greater than 
60 mL/min, randomized to receive either lisinopril plus 
placebo, or lisinopril plus telmisartan. The patients were 
further randomized to treatment groups consisting of stan-
dard blood pressure control (120–130/70–80 mmHg) versus 
rigorous BP control (95–110/65–75 mmHg). Study B consists 
of 472 patients with GFRs ranging from 25 to 60 mL/min, 
again randomized to receive either lisinopril plus placebo 
or lisinopril plus telmisartan. The authors hypothesize that 
intense blockade of RAAS using the combination of ACE 
inhibitors and ARBs will delay the onset and progression of 
renal disease in ADPKD patients, with rigorous blood pres-
sure control being most effective in limiting the progression 
of renal disease early on in ADPKD. At the completion of 
the study, the investigators hope to obtain better evidence 
for treatment of ADPKD-associated hypertension in early 
and late stages of disease.1,2
Other RAAS inhibiting agents that may hold promise 
in the future include the direct renin inhibitors, which have 
been shown to reduce blood pressure in a dose-dependent 
manner, reduce plasma renin activity, and decrease protei-
nuria while delaying renal failure in patients with diabetic 
and nondiabetic nephropathy.117 Long-term studies of the 
effects of this treatment class, in addition to comparisons 
with other RAAS inhibiting agents, are required before a 
conclusion can be made about its utility in renovascular 
conditions such as ADPKD.
Regardless of the agent utilized, tight blood pressure 
control has been shown to delay the progression of disease 
in ADPKD. Other currently-accepted treatment strategies 
in ADPKD include salt-restriction (no more than 6 grams 
of sodium chloride daily), low protein intake (no more than 
1 gram per kilogram of body weight per day), regular exer-
cise, maintenance of a healthy body weight, and frequent 
water intake.118
Dialysis
Dialysis is a common means of renal replacement therapy 
for patients with PKD awaiting kidney transplants. Options 
for PKD patients include both hemodialysis and peritoneal 
dialysis, though the latter is commonly thought to lead to 
poor outcomes due to concerns of abdominal wall compli-
cations, including leaks and intestinal perforation, in part 
due to increased intraabdominal pressure resulting from 
large kidney volumes.119–121 However, in a retrospective 
study of 56 patients with PKD receiving peritoneal dialysis, 
Kumar et al found no difference in patient survival, technique 
survival, and peritonitis rates after a mean of 37 months 
follow-up in PKD patients compared to nondiabetic ESRD 
controls.122 Increased intraabdominal pressure can make 
peritoneal dialysis more difficult, however, preventing the 
use of larger dwell volumes. Hemodialysis has also been 
shown to be an effective and safe means of renal replacement 
in ADPKD patients, with a 5-year survival 10%–15% higher 
than non-ADPKD controls, most likely related to decreased 
cardiac mortality in this group of patients.123
Transplant
ADPKD is a common cause of ESRD, requiring renal trans-
plantation. In a 2009 study of 445 renal transplant patients, 
48 of whom had ADPKD, the average age at transplant for 
ADPKD patients was found to be 51.2 ± 8.6, with there 
being no significant differences between ADPKD and 
other renal transplant patients in terms of the prevalence 
of post-transplant hypertension, proteinuria, erythrocy-
tosis, acute rejection episodes, immediate graft function, 
and most importantly, graft and patient survival after 1, 
5, and 8 years.124 ADPKD patients did, however, have a 
significantly-increased incidence of developing diabetes 
mellitus post-transplant compared to non-ADPKD patients 
(33.3% vs 17.1%). Simultaneous nephrectomy at the time 
of transplant can also be performed and has been shown 
in a recent study of 20 patients undergoing the procedure 
to produce minimal morbidity while avoiding the risks of 
interval dialysis, additional operations, hospitalizations, 
and anesthetic exposure.125 This combined approach is not 
without its potential complications, however, found in the 
study to include one instance of wound dehiscence, adrenal 
insufficiency, and liver laceration. Although the best patient 
population for this approach has not been defined, it has been 
suggested that the risks of this procedure are best managed in 
the setting of a skilled team consisting of a donor surgeon, a 
urologist, a transplant surgeon, and an adept anesthesiologist, 
in an institution with a high number of cases.125
Symptomatic treatment
Treatment of ADPKD is focused on prophylactic and sup-
portive measures, which, in addition to tight blood pressure 
management, include adequate pain control, antibiotics for 
urinary tract infections, sufficient fluid intake, and avoid-
ance of caffeine and smoking.2,11,40 Urinary tract infec-
tions are common during the disease course of ADPKD. 
Typically, upper and lower urinary tract infections present 
similarly to patients without ADPKD, and are treated in the 
same fashion, using cyst-penetrating antibiotics including 
trimethoprim-sulfamethoxazole and fluoroquinolones.126,127 International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Of note, patients with parenchymal and cyst involvement can 
present with a urinary tract infection and negative urinary 
cultures, as not all cysts communicate with the urinary space. 
This presentation should be suspected in patients with a pro-
longed fever, weight loss, and non-specific gastrointestinal 
symptoms.
The significant abdominal, back, and flank pain associ-
ated with ADPKD is often severe enough to interfere with 
activities of daily living.128 This occurs either as a result of 
mass effect from the enormous growth of the kidneys, or 
more acutely due to individual cyst rupture, with pain most 
frequently occurring in the lower back or abdomen.129 Pain 
management can be difficult in these patients as standard 
approaches, including use of non-steroidal agents, should be 
avoided, given their effect on the kidneys. Use of narcotic 
analgesics should be reserved for acute episodes to mini-
mize the potential for dependence. Despite these strategies, 
anywhere from 50%–70% of patients with ADPKD have 
pain that is uncontrolled with oral analgesics.130 Accord-
ingly, when conservative measures fail, surgical options 
are available. These include cyst decortication, which is 
now performed laparoscopically and has been found in a 
study of 29 ADPKD patients to result in a greater than 50% 
improvement in pain in 73%, 52%, and 81% of patients, at 
12, 24, and 36 months, respectively.131 Similarly, a differ-
ent study of 15 ADPKD patients treated with laparoscopic 
decortication revealed that pain decreased an average of 
62% in 73% of cases at a mean follow-up of 2.2 years 
(range 0.5–5).132 Further studies are needed to determine 
the benefits of decortication for longer-term pain relief. 
Nonetheless, this is not an entirely benign procedure, with 
reported complications including postoperative bleeding, 
ileus, worsening hypertension, arrhythmia, pneumonia, and 
even death.133–135 An additional option that holds promise 
in treating symptoms associated with the mass effect of 
the kidneys includes renal artery embolization. This proce-
dure involves embolization of the main renal artery, although 
selective embolization has been attempted. It is typically 
performed only on dialysis-dependent patients as it elimi-
nates any remaining renal function, essentially decreasing 
GFR to zero. This is important to consider in those ESRD 
patients with some residual renal function, as renal artery 
embolization will eliminate this remaining function and its 
potential quality of life benefits. Nonetheless, the procedure 
has been shown in a number of studies to effectively treat 
hematuria and decrease kidney size, with only minimal 
side effects that include temporary flank pain, fever, and 
nausea and vomiting.136,137 The data supporting use of this 
modality over other more invasive approaches is limited, 
and open or laparoscopic nephrectomy with transplantation 
remains the treatment of choice in patients with ESRD and 
intractable pain.17 Nonetheless, embolization seems to be an 
effective option in ADPKD patients and may be most useful 
in those in which transplantation is not possible.138
Other indications for nephrectomy in ADPKD patients 
with ESRD include cyst rupture, hemorrhage, renal calculi, 
hypertension, and persistent infection.139 When conservative 
measures fail, explantation may also be utilized to relieve 
mass effect symptoms, including pain, shortness of breath, 
and early satiety resulting from renal displacement of 
adjacent structures and organs, with a 2000 study showing 
complete elimination of preoperative pain in all 9 patients 
undergoing laparoscopic nephrectomy.140
Cases of nephrolithiasis can generally be treated with 
conservative measures including hydration, analgesia, and 
treatment of any associated infections.24 Potassium citrate 
can also be utilized in cases of uric acid nephrolithiasis, 
  hypocitraturic calcium oxalate nephrolithiasis, and distal 
acidification defects.12 When conservative measures fail, alter-
native approaches to stone therapy may include extracorporeal 
shockwave lithotripsy and percutaneous nephrostolithotomy. 
Prophylactic measures should include good water intake.
Novel therapies
mTOR inhibitors
Characteristic to ADPKD is enhanced renal tubular epi-
thelial cell proliferation, which has been shown in humans 
and animal models of ADPKD to be related to activation of 
the mTOR pathway.2,141,142 Accordingly, novel therapies for 
ADPKD include use of inhibitors of the mTOR pathway, 
with agents that include rapamycin and everolimus, shown 
in animal models to slow cyst expansion and preserve renal 
function.141–143
Recent evidence for the use of rapamycin in humans 
comes from a 2009 randomized, single-blind study that 
followed 8 patients with ADPKD treated with 1 mg/day 
of rapamycin by mouth daily for 6 months, in addition to 
the angiotensin receptor blocker, telmisartan.144 Another 
8 patients with ADPKD received only telmisartan, represent-
ing the control group. All the patients involved in the study 
had creatinines under 2.0 mg/dL, with negative urine cultures, 
prior to the beginning of the study. Of the patients who were 
treated with rapamycin, 5/8 had stable renal function at the 
study’s completion, with 2 showing improved renal func-
tion and 1 demonstrating a worsening creatinine, resulting 
in the patient withdrawing from the study. In contrast, of International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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the control patients receiving only the ARB, renal function 
remained stable in 3, became worse in 3, and improved in 2. 
Complications in the treatment group included urinary tract 
infection in 2 patients, and monilial pharyngitis in another 2, 
compared to only 2 infections in the control group. Most 
notably, MRIs obtained at the beginning of the study and 
again following 6 months of therapy revealed a significant 
rise in kidney volume in the control group (from 2667 mL 
to 3590 mL at 6 months), compared to the treatment group, 
who experienced a much smaller volume increase (2845 mL 
to 3221 mL at 6 months). Accordingly, the authors conclude 
that rapamycin may prove to be beneficial, in combination 
with an ARB, in the treatment of ADPKD. Confirmatory 
studies, with longer follow-up and greater numbers of 
patients are currently underway, with definitive data expected 
to be available in 2010.2
Vasopressin receptor antagonists
In addition to mTOR-regulated cell proliferation, cyst forma-
tion and growth is thought to be due in part to enhanced fluid 
secretion from renal tubular epithelial cells. This process of 
fluid secretion is driven by a number of signaling cascades, 
including those related to cAMP generation. Accordingly, 
agents that disrupt this pathway, such as vasopressin recep-
tor antagonists, have been considered to be a potential 
treatment approach. Vasopressin receptor antagonists act 
by disrupting the binding of vasopressin to V2 receptors 
normally expressed in kidney collecting ducts, the primary 
location where ARPKD cysts derive, and possibly ADPKD 
as well.145 Normally, upon binding to V2 receptors, vaso-
pressin stimulates adenylyl cyclase to produce cAMP, 
stimulating cyst formation and growth through promotion 
of fluid secretion and proliferative activity of cyst epithelial 
cells.40,146 Accordingly, since patients with PKD have been 
found to have elevated vasopressin levels, by blocking this 
pathway, it was thought that disease progression may be 
disrupted and potentially inhibited when treated early in the 
disease course.147–149 This has been shown in a number of 
studies, first in a 1999 study by Gattone et al which found that 
OPC-31260, a V2 receptor antagonist, led to amelioration of 
cystic enlargement and azotemia in a cpk mouse, a model of 
rapidly progressive cystic disease.145 Subsequent studies have 
produced similar results using OPC-31260 in animal models 
orthologous to human ADPKD, ARPKD (PCK rat), and ado-
lescent nephronophthisis.146,150 Other studies have shown that 
tolvaptan, a vasopressin receptor antagonist FDA approved 
for the treatment of clinically-significant hypervolemic and 
euvolemic hyponatremia, may also be effective in animal 
models of PKD, with this drug having even stronger V2 
binding.151 Accordingly, a number of studies analyzing the 
effects of tolvaptan in humans have been undertaken as part 
of the Tolvaptan Efficacy and Safety in Management of PKD 
and Outcomes (TEMPO) program, in order to more definitely 
define its potential role in ADPKD. Results from the phase 2 
component of the study have found tolvaptan to be safe and 
well-tolerated in ADPKD.145 A large, placebo-controlled, 
double-blind study, representing phase 3 of the program is 
currently in progress, studying 18 to 50-year-old patients 
with ADPKD, preserved renal function, and relatively rapidly 
progressing disease, as defined by total kidney volumes over 
750 mL (TEMPO 3/4 study; NCT00428948).2,145 Results of 
the study should clarify the efficacy of tolvaptan in slowing 
disease progression.
Octreotide
Octreotide has therapeutic potential via inhibition of cAMP 
production.40 Somatostatin was first thought to be a poten-
tial treatment option for patients with ADPKD after it was 
incidentally found that a patient with ADPKD and a pituitary 
adenoma being treated with somatostatin had stabilization of 
their renal cyst size.152 Somatostatin has since been shown 
in animal models to lower serum cAMP levels and reduce 
kidney weights, cyst volumes, and renal fibrosis in PCK 
rats, although it has not been found to have any effect on 
renal function.153 In humans, octreotide has been shown in 
a 6 month, randomized, cross-over, placebo-controlled trial 
to be well-tolerated and to significantly slow renal volume 
expansion, particularly by retarding the growth of smaller 
sized cysts.152 Again, notably, octreotide was found to have 
no effect on GFR compared to controls. Long term benefits of 
the drug remain unknown, with studies underway to further 
evaluate somatostatin’s role in treatment.40
Additional agents
Other investigational agents in ADPKD include roscovitine, 
triptolide, pioglitazone, and etanercept, the roles of which 
may become more clear with time.40 As more data becomes 
available about the many investigational drugs being tested 
in PKD (Table 3), new treatment recommendations may 
become available that could benefit these patients. In the 
meantime, patients should be advised to follow current 
management recommendations.
ARPKD
Disease-specific therapies for ARPKD are lacking, and treat-
ment is therefore directed towards management of   associated International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Table 3 Select novel therapies in PKD
Drug name/class Mechanism of action Supporting data
mTOR inhibitors Inhibition of mTOR signaling 
cascade, disrupting renal 
epithelial cell proliferation
Randomized, single-blind study 
showing significant slowing of renal 
size in patients treated with 
rapamycin and telmisartan, compared 
to telmisartan alone
Vasopressin receptor 
antagonists
Disruption of binding of 
vasopressin to V2 receptors, 
inhibiting cAMP-associated 
signaling cascades
Phase 2 results show tolvaptan to be 
safe and well-tolerated; phase 3 
studies in progress
Octreotide Inhibition of cAMP production Shown in a randomized, cross-over, 
placebo-controlled trial to 
significantly slow renal volume 
expansion; no effect on GFR
Abbreviations: mTOR, mammalian target of rapamycin; cAMP, cyclic adenosine monophosphate.
complications, which commonly include respiratory 
  insufficiency, hypertension, growth retardation, electrolyte 
abnormalities, hepatic manifestations, and acute and chronic 
renal insufficiency.36 Respiratory complications in ARPKD 
can be severe and may require prolonged mechanical venti-
lation and neonatal intensive care support. Hypertension in 
these patients often requires multiple antihypertensive agents 
and is typically responsive to ACE inhibitors.36 Growth retar-
dation related to increased metabolic demands, poor feeding, 
and early satiety can be addressed with gastrostomy or naso-
gastric tubes feedings. Electrolyte abnormalities, including 
hyponatremia, should be treated as needed, and may require 
changes in water and sodium intake.104 Congenital hepatic 
fibrosis and its associated complications should be followed 
closely by pediatric gastroenterologists, and may require 
periodic endoscopy with variceal banding, as well as porto-
systemic shunting. ESRD is treated with renal replacement 
therapies, including dialysis and renal transplantation.
Conclusion
Autosomal dominant polycystic kidney disease is one of 
the most common inheritable conditions. With an incidence 
10 times that of sickle cell disease and 15 times that of cystic 
fibrosis, effective treatment options for ADPKD are widely 
sought, but remain an elusive goal.23 Recent advances in the 
understanding of the genetic and molecular pathogenesis of 
both ADPKD and ARPKD have resulted in new, targeted 
therapies designed to disrupt cell signaling pathways respon-
sible for the abnormal cell proliferation, dedifferentiation, 
apoptosis, and fluid secretion characteristic of the disease.40 
Although definitive cures are still lacking, many of these 
newer therapeutic agents show promise in preventing or 
stabilizing cyst growth, providing much needed hope in this 
currently relentless condition.
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